Boston Scientific

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against iRhythm, Hut 8, and Xponential and Encourages Investors to Contact the Firm

Retrieved on: 
Friday, February 16, 2024
Bitcoin, Geisler, Data mining, Zio, Vii, Boston Scientific, Research, FDA, J. P. Morgan, Marketing, News, Growth, Sale, SSS, ECG, Stroke, AUV, Heart failure, Hut 8, Atrial fibrillation, Bankruptcy, Mergers and acquisitions, IRTC, DOJ, Bloomberg Businessweek, Patient, Defendant, Justice, Subpoena duces tecum, P.C, Cryptocurrency

The Company’s principal product is a monitoring patch that provides electrocardiogram (“ECG”) monitoring for up to 14 days, called Zio XT.

Key Points: 
  • The Company’s principal product is a monitoring patch that provides electrocardiogram (“ECG”) monitoring for up to 14 days, called Zio XT.
  • The Zio XT is intended for non-critical patients, as it does not provide real-time reporting.
  • As a result of these misrepresentations, the price of iRhythm common stock traded at artificially inflated prices throughout the Class Period.
  • For more information on the Xponential class action go to: https://bespc.com/cases/XPOF

IRHYTHM INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In iRhythm To Contact Him Directly To Discuss Their Options

Retrieved on: 
Thursday, February 15, 2024
Zio, Court, Boston Scientific, Marketing, FDA, J. P. Morgan, Advertising, Growth, Woman, IRTC, DOJ, Patient, LLP, Justice, Subpoena duces tecum, Cryptocurrency

NEW YORK, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against iRhythm Technologies, Inc. (“iRhythm” or the “Company”) (NASDAQ: IRTC) and reminds investors of the April 8, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Key Points: 
  • Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • The complaint alleges that, throughout the Class Period, Defendants falsely represented to investors that the Zio AT monitor was a real-time monitor intended for high-risk patients.
  • As a result of these misrepresentations, the price of iRhythm common stock traded at artificially inflated prices throughout the Class Period.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding iRhythm’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Acarix Strengthens U.S. Team with Three Key Advisors

Retrieved on: 
Thursday, February 15, 2024
Biotelemetry, Boston Scientific, Cardiology, Novo Nordisk, Medtech, Knowledge, Publication

NEW YORK, Feb. 15, 2024 /PRNewswire/ -- Acarix, a leader in advanced acoustic-based cardiac diagnostics, announces the appointment of three new advisors to its team.

Key Points: 
  • NEW YORK, Feb. 15, 2024 /PRNewswire/ -- Acarix, a leader in advanced acoustic-based cardiac diagnostics, announces the appointment of three new advisors to its team.
  • Acarix, a leader in advanced acoustic-based cardiac diagnostics, announces the appointment of three new advisors.
  • His clinical and business expertise will provide the Acarix team with a fresh new viewpoint of the U.S. market.
  • "I am pleased to welcome Mr. Nelson, Dr. Oza, and Mr. Braun to the Acarix team," stated Aamir Mahmood, President & CEO of Acarix.

Dave Amerson and Tyler Binney Add Their Experience Commercializing Disruptive Technologies to Intrinsic Therapeutics' Board of Directors

Retrieved on: 
Tuesday, February 13, 2024
Earnout, Acquisition, Intrinsic and extrinsic properties, Boston Scientific, Teleflex, Argosy University, FDA, Marketing, Growth, Johnson & Johnson, University, Therapy, Management

"We are thrilled to welcome these two highly regarded industry leaders to our board," said Cary Hagan, President and CEO.

Key Points: 
  • "We are thrilled to welcome these two highly regarded industry leaders to our board," said Cary Hagan, President and CEO.
  • "Dave and Tyler bring a wealth of experience in launching disruptive technologies and developing high-growth companies and will provide invaluable guidance as we aggressively expand our sales activities this year.
  • With these board additions, Intrinsic is well-positioned to rapidly increase patient access to Barricaid."
  • Dave Amerson served as President and CEO of NeoTract, Inc. until its acquisition by Teleflex in 2017 for $1.1 billion.

HemoSonics' Quantra® Hemostasis System Named as a Finalist in the World Renowned 2024 Edison Awards

Retrieved on: 
Tuesday, February 13, 2024
Thomas Edison, Engineering, Cartridge, Hospital, Boston Scientific, Caregiver, Elasticity, Biotechnology, Education, Marketing, FDA, Gold, Health, Intensive care medicine, Edison Awards, GE HealthCare, Medtech, Patient, Operating, Apple, Lockheed, Science, Silver, Pharmaceutical industry

DURHAM, N.C., Feb. 13, 2024 /PRNewswire/ -- HemoSonics, LLC, a medical device company focused on acute bleeding management, today announced that its Quantra Hemostasis System with QPlus® and QStat® Cartridges has been named a finalist in the 2024 Edison™ Awards. The company was honored in the health, medical, and biotechnology category for its Quantra Hemostasis System. The Quantra System with QPlus and QStat Cartridges provides comprehensive whole-blood coagulation analysis at the point of care in less than 15 minutes.

Key Points: 
  • The company was honored in the health, medical, and biotechnology category for its Quantra Hemostasis System.
  • The Quantra System with QPlus and QStat Cartridges provides comprehensive whole-blood coagulation analysis at the point of care in less than 15 minutes.
  • Named after the American inventor Thomas Alva Edison, the Edison Awards recognize the world's most innovative products and business leaders, including Steve Jobs, Jony Ive, Gwynne Shotwell, Ginni Rometty, Apple, Nest, 3M, Lockheed Martin and many more.
  • The Quantra Hemostasis System consists of the Quantra Hemostasis Analyzer with QPlus and QStat Cartridges.

SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates AXNX, PGTI, EGLE, BBAI

Retrieved on: 
Saturday, February 10, 2024
Boston Scientific, Fraud, Sale, PGT, Advertising, Holding, Security (finance)

If you are an Axonics shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are an Axonics shareholder, click here to learn more about your rights and options .
  • If you are a PGT shareholder, click here to learn more about your rights and options .
  • Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

IRHYTHM DEADLINE ALERT: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In iRhythm To Contact Him Directly To Discuss Their Options

Retrieved on: 
Thursday, February 8, 2024
Justice, IRTC, FDA, DOJ, Advertising, Woman, Growth, Boston Scientific, Subpoena duces tecum, Marketing, Zio, Patient, J. P. Morgan, LLP, Court, Pharmaceutical industry

NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against iRhythm Technologies, Inc. (“iRhythm” or the “Company”) (NASDAQ: IRTC) and reminds investors of the April 8, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Key Points: 
  • If you suffered losses exceeding $100,000 investing in iRhythm stock or options between January 11, 2022, and May 30, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext.
  • Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • As a result of these misrepresentations, the price of iRhythm common stock traded at artificially inflated prices throughout the Class Period.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding iRhythm’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

IRHYTHM ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against iRhythm Technologies, Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, February 8, 2024
Atrial fibrillation, Growth, Telephone, IRTC, Patient, P.C, FDA, Marketing, Justice, Boston Scientific, ECG, DOJ, District court, Zio, Heart failure, J. P. Morgan, Stroke, Subpoena duces tecum, Court, Person, Medical device

Investors have until April 8, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until April 8, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • iRhythm develops and manufactures heart monitoring devices designed to diagnose arrythmias.
  • The Company’s principal product is a monitoring patch that provides electrocardiogram (“ECG”) monitoring for up to 14 days, called Zio XT.
  • As a result of these misrepresentations, the price of iRhythm common stock traded at artificially inflated prices throughout the Class Period.

Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of iRhythm Technologies, Inc. (IRTC) Investors

Retrieved on: 
Wednesday, February 7, 2024
Class Action Lawsuit, Professional Services, Legal, Growth, News, IRTC, Patient, FDA, Marketing, Justice, Boston Scientific, DOJ, District court, Zio, J. P. Morgan, Subpoena duces tecum, LLP, Court, Pharmaceutical industry

Investors have until April 8, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until April 8, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • The lawsuit alleges that, throughout the Class Period, iRhythm failed to disclose serious issues with its Zio AT heart monitor to the FDA, patients, or investors.
  • As a result of these representations, the price of iRhythm common stock traded at artificially inflated prices throughout the Class Period.
  • Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation.

Shareholder Alert: Bernstein Litowitz Berger & Grossmann LLP Announces the Filing of Securities Class Action Lawsuit Against iRhythm Technologies, Inc.

Retrieved on: 
Wednesday, February 7, 2024
Class Action Lawsuit, Professional Services, Legal, Pension, Atrial fibrillation, Class, Growth, BLB, Patient, Complaint, FDA, Marketing, Justice, Boston Scientific, ECG, DOJ, District court, Action Replay, Zio, Heart failure, J. P. Morgan, Stroke, Subpoena duces tecum, Court, Person, Medical device

The action is brought on behalf of all persons or entities that purchased or otherwise acquired iRhythm common stock between January 11, 2022, and May 30, 2023, inclusive (the “Class Period”).

Key Points: 
  • The action is brought on behalf of all persons or entities that purchased or otherwise acquired iRhythm common stock between January 11, 2022, and May 30, 2023, inclusive (the “Class Period”).
  • The complaint is based on an extensive investigation and a careful evaluation of the merits of this case.
  • The Company’s principal product is a monitoring patch that provides electrocardiogram (“ECG”) monitoring for up to 14 days, called Zio XT.
  • As a result of these misrepresentations, the price of iRhythm common stock traded at artificially inflated prices throughout the Class Period.